Back to results
US 6,730,684 B1Granted
Fab I inhibitors
AssigneeAffinium Pharmaceuticals, Inc.
InventorsWilliam H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infections.
Claims17
A compound according to formula (I) or (II):
- wherein:
- R1 is H or C1-4alkyl;
- R2 is C1-4alkyl;
- R3 is
- Q is a single bond, —O—, —S—, —NH—, —CH2—, or —CH2CH2—;
- R4 is C1-6alkyl, OC1-6alkyl, OH, CF3 or piperidinyl;
- is a five- or six-membered heteroaromatic ring or a six-membered aromatic ring unsubstituted or substituted by R5;
- is a five- or six-membered heteroaromatic ring or a six-membered aromatic ring unsubstituted or substituted by R6;
- is a five- or six-membered heteroaromatic ring or a six-membered aromatic ring unsubstituted or substituted by R6;
- R5 is OR′ or NR′C(O)R′;
- R6 is OR′ or N(R′)2;
- X is H, C1-4alkyl, OR′, SR′, CN, N(R′)2, CH2N(R′)2, NO2, CF3, CO2R′, CON(R′)2, COR′, NR′C(O)R′, F, Cl, Br, I or —S(O)rCF3;
- R′ is H, C1-6alkyl or —C0-6alkyl-Ar;
- and
- r is 0, 1 or 2;
- or a pharmaceutically acceptable salt thereof.
13 more elements
Dependencies are inferred from the claim text.